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IL-1β-induced anorexia may depend on interactions of the cytokine with neuropeptides and neurotransmitters of
the central nervous system control of energy balance and serotonin is likely to be one catabolic mediator targeted
by IL-1β. In the complex interplay involved in feeding modulation, nitric oxide has been ascribed a stimulatory
action, which could be of significance in counteracting IL-1β effects.
The present study aims to explore the participation of the nitric oxide and the serotonin systems on the central
mechanisms induced by IL-1β and the relevance of their putative interactions to IL-1β hypophagia in normal rats.
Serotonin levels were determined in microdialysates of the ventromedial hypothalamus after a single
intracerebroventricular injection of 10 ng of IL-1β , with or without the pre-injection of 20 μg of the nitric oxide
precursor L-arginine. IL-1β significantly stimulated hypothalamic serotonin extracellular levels, with a peak variation
of 130 ±37% above baseline. IL- 1β also reduced the 4-h and the 24-h food intakes (by 23% and 58%, respectively).
The IL-1β-induced serotonergic activation was abolished by the pre-injection of L-arginine while the hypophagic
effect was unaffected.
The data showed that one central effect of IL-1β is serotonergic stimulation in the ventromedial hypothalamus, an
action inhibited by nitric oxide activity. It is suggested that, although serotonin participates in IL-1β anorexia, other
mechanisms recruited by IL-1β in normal rats are able to override the absence of the serotonergic hypophagic
influence.
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It is well known that chronic inflammatory states are asso-
ciated with loss of appetite, contributing to muscle and
adipose tissue wasting, debilitation of defenses and im-
paired prognosis [1]. An action of the pro-inflammatory
cytokine interleukin-1β (IL-1β) at central nervous system
sites has been implicated in the pathogenesis of anorexia
[2]. Additionally, there have been reports on a possible
participation of brain IL-1β activity in the physiological
mechanisms controlling feeding and energy homeostasis
[3,4]. These homeostatic mechanisms are complex and* Correspondence: eliane.beraldi@gmail.com
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reproduction in any medium, provided the orinclude multiple mediators whose interactions are not
completely understood [5,6].
There is evidence that the mechanisms of IL-1β anorexia
involve interactions of the cytokine with hypothalamic
neuropeptides and neurotransmitters of the energy balance
control system [7,8]. Among the numerous factors acting
at the hypothalamus to influence energy balance, serotonin
(5-HT) inhibits food intake and stimulates energy expen-
diture [5,9]. The demonstrations that 5-HT receptor anta-
gonism or inhibition of 5-HT synthesis attenuated central
IL-1β anorexia suggested a serotonergic mediation for this
IL-1β effect [10,11].
Central nitric oxide (NO) activity has been implicated
in the modulation of food intake, with an orexigenic ef-
fect being suggested by the findings that NO-synthase
(NOS) inhibition led to hypophagia in mice and rats andd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Iuras et al. Journal of Neuroinflammation 2013, 10:147 Page 2 of 7
http://www.jneuroinflammation.com/content/10/1/147that animal models of obesity have a hyperactive brain
NO system [12-14]. In a previous study, we used brain
microdialysis to address the question of whether the 5-
HT system in the ventromedial hypothalamus (VMH)
participates in the anorexia induced by IL-1β in obese
Zucker rats. We found that 5-HT release was highly
stimulated by a single intracerebroventricular (i.c.v) in-
jection of IL-1β, which also significantly inhibited food
intake. The importance of the serotonergic activation to
IL-1β effect in the obese rats was confirmed by the dem-
onstration that pre-treatment with L-arginine (ARG),
the precursor for the synthesis of NO by the NOS, abo-
lished both serotonergic stimulation and the hypophagia
induced by IL-1β [15].
The suppression of IL-1β effects by a treatment leading
to increased NO production conflicts with the reported
higher NOS-2 expression in various brain areas after acute
IL-1β in rats [16-18]. On the other hand, other authors
have provided evidence for a reciprocal relationship
between central NO and 5-HT metabolism [19-21].
The present study aims to investigate the putative
functional interactions of the hypothalamic serotonergic
system and the NO system and their relevance to the
feeding effect of IL-1β in normal rats.
Materials and methods
Animals and surgery
The present study was approved by the Committee on
Animal Research Ethics of the Federal University of São
Paulo. In accordance with the Committee’s guidelines, the
number of animals used and their suffering were kept to a
minimum.
Since weaning, male lean Zucker rats (Fa/?) were
housed five per cage and maintained in controlled con-
ditions of lighting (12:12 h light-dark cycle, lights off at
18:00 h) and temperature (24 ±1°C), with free access to
standard balanced chow (4% fat, 22% protein, Nuvital
Nutrients, Columbo, PR, Brazil) and water.
At 4 months of age they were anesthetized with keta-
mine/xylaxine (67/13 mg/kg) and implanted with both
a 21-gauge guide cannula aimed at the VMH (A −2.5,
L −0.6, and V −6.9 from Bregma) and a 23-gauge can-
nula aimed at the lateral ventricle (A −0.9, L +1.6, and
V −2.5 from Bregma) [22]. The cannulas were secured
to the skull with screws and dental cement; the animals
were individually caged and maintained with food and
water ad libitum thereafter. For measurement of the ef-
fect of drug treatments on food intake, a separate group
of animals received only the i.c.v. cannula. All animals
were used after eight days of surgery.
Measurement of food intake
The animals were fasted for 20 hours and received one
of the following i.c.v. treatments (5.0 μL): artificialcerebrospinal fluid (CSF), 20 μg ARG (Sigma), 10 ng IL-
1β (IL, Upstate) or 20 μg ARG followed by 10 ng IL-1β
(ARG + IL, with a 2-h interval between injections). Pre-
weighed food cups were then introduced in the cages
and the intake measured after 4 and 24 h. The ARG
dose was based on its lack of an effect on 24-h feeding
[21] while the IL-1β dose was chosen due to its ability to
inhibit feeding [7].
Microdialysis experiments
A concentric custom-constructed microdialysis probe
(2.0 mm of effective membrane length) was inserted
through the VMH guide cannula and fixed to it with a
small drop of dental cement. Probe construction was de-
tailed elsewhere [23-25]. The animal was connected to a
swivel system and the probe perfused overnight, at
1.0 μL/min, with artificial CSF (145 mM NaCl, 2.7 mM KCl,
1.0 mM MgCl2, 1.2 mM CaCl2, 2.0 mM Na2HPO4, pH 7.4).
Food was removed immediately after probe insertion.
The next morning, the flow rate was adjusted to 2.5 μL/
min; 20-min dialysate samples were collected into 10 μL
of 0.5 M perchloric acid and immediately injected into a
high performance liquid chromatography (HPLC) system.
Baseline samples were collected until 5-HT levels were
stable, and then i.c.v. injections were started, typically
around noon. A mean baseline level (100% value) was cal-
culated by averaging the three basal samples obtained just
prior to the i.c.v. injections of 5.0 μL of artificial CSF or 20
μg ARG. After the collection of six 20-min microdialysate
samples, all animals received a 10 ng injection of IL-1β.
Nine additional 20-min samples were collected.
HPLC analysis
Dialysate levels of 5-HT and 5-hydroxy-indol-acetic acid
(5-HIAA) were measured by HPLC with electrochemical
detection. The system (ESA Inc., Chelmsford, MA, USA)
consisted of a model 580 pump with two PEEK pulse
dampers in series, a 50 μL Rheodyne PEEK sample loop,
a 3-μm MD150 C column, a model 5020 guard cell set
at 300 mV, a model 5014B analytical cell set at −175 and
150 mV, and a model 5200A detector. The mobile phase
consisted of 75 mM sodium phosphate, 1.5 mM octane-
sulfonic acid, 50 μM EDTA, 100 μL/L triethylamine, and
10% v/v acetonitrile at pH 3.0. The flow rate was 0.6
mL/min. The detection limit for 5-HT was 1.5 pg/50 μL
at a signal to noise ratio of 3:1 [25].
Histological analysis
For verification of probe and i.c.v. cannula positioning,
at the termination of the experiments the animal was
deeply anesthetized and decapitated. The brain was re-
moved and 50-μm sections were examined under a micro-
scope, following staining with Cresyl Violet. The animals
used in the experiments of food intake were injected with
50
100
150
200
250
-40 -20 0 20 40 60 80 100 120
Minutes after injection
5-
H
T 
(%
)
CSF ARG
50
100
150
200
250
-40 -20 0 20 40 60 80 100 120 140 160 180
Minutes after IL-1 injection
5-
H
T 
(%
)
ARG + IL
*
**
#
**
*
*
*
Figure 1 Effect of ARG and IL-1β on hypothalamic 5-HT levels.
Serotonin levels, expressed as % of the mean basal level, in 20-min
VMH microdialysate samples. Upper Panel: Samples collected before
or up to 120 min after the i.c.v. injection of 20 μg of L-arginine (ARG,
n = 8) or vehicle (CSF, n = 9). Values are means ±S.E.M. Lower Panel:
Samples collected before or up to 180 min after the i.c.v. injection of
10 ng of interleukin-1β, in animals pretreated with 20 μg L-arginine
(ARG + IL-1β, n = 8) or not (IL-1β, n = 9). Values are means ±S.E.M.
*P <0.05 compared with the respective pre-injection levels. # P <0.05
compared with ARG pre-treatment.
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tribution was examined. Only the animals in which the
correct placements of dialysis membrane and i.c.v. can-
nula were confirmed were included in the data analysis.
Data analysis
The results are shown as means ± S.E.M. The 5-HT and
5-HIAA data were submitted to two-way repeated mea-
sures ANOVA followed by the Tukey post hoc test. Food
intake results were compared by ANOVA for independent
measures and Tukey test. Significance was set at P <0.05.
Results
Effect of the i.c.v. treatments on 4-h and 24-h food intake
In comparison to CSF treatment, the injection of IL-1β
significantly reduced both the 4-h and the 24-h intake.
Pre-treatment with ARG did not modify IL-1β hypopha-
gia. The injection of ARG alone increased the 4-h intake
but not the 24-h intake (Table 1).
5-HT and 5-HIAA levels in VMH microdialysates
Mean basal levels of 5-HT and 5-HIAA in the VMH
microdialysates were 2.36 ±0.40 pg/50 μL and 230 ±0.06
pg/50 μL, respectively. The treatments with either ve-
hicle or ARG failed to cause significant variations in
serotonin levels (F(8, 120) = 1.324, P = 0.238) and there
was no significant time-treatment interaction (F(8, 120) =
0.748, P = 0.649) (Figure 1, upper panel).
Treatment with IL-1β had a significant interaction
with sampling time (F(11, 165) = 5.885, P <0.001). The in-
jection of IL-1β in the animals not pre-treated with ARG
evoked significant increments of 5-HT microdialysate
levels. The values were significantly increased from base-
line from the second to the ninth sample collected after
IL-1β injection. On the other hand, the injection of IL-
1β after the ARG pre-injection failed to significantly
affect 5-HT levels (Figure 1, lower panel).
5-HIAA levels did not show any significant variations
during the 2 h following the injection of CSF or ARG
(F(8, 120) = 0.719, P = 0.67) and no significant time-Table 1 Food intake during the 4 hours and the 24 hours
after an i.c.v. injection of artificial cerebrospinal fluid
(CSF, n = 10), 20 μg of L-arginine (ARG, n = 8), 10 ng of
interleukin-1β (IL-1β, n = 10), or 20 μg L-arginine followed
2 h later by 10 ng of interleukin-1β (ARG + IL-1β, n = 8)
Food intake (g/100 g b.w.)
Treatment 4 hours 24 hours Body weight
CSF 1.87 ±0.09 7.88 ±0.45 329 ±8
ARG 2.56 ±0.17* 8.50 ±0.51 348 ±9
IL-1β 1.44 ±0.17* 4.98 ±0.96* 317 ±7
ARG + IL-1β 1.51 ±0.11* 5.13 ±0.22* 326 ±7
*P <0.05 vs. CSF treatment.treatment interaction was detected (F(8, 120) = 1.835, P =
0.077). The injection of IL-1β failed to modify 5-HIAA
levels (F(11,165) = 1.275, P = 0.242) with no time-treatment
interaction F(11,165) = 0.764, P = 0.675) (Figure 2).
Discussion
The present data confirmed the ability of IL-1β to inhibit
food intake when injected into the central nervous sys-
tem [7,15,26,27]. This finding reinforces the idea that IL-
1β anorexia relies on central actions of the cytokine. We
performed a series of experiments aimed at contributing
to the understanding of the mechanisms used by IL-1β.
Peripherally-administered IL-β has been shown to in-
duce neuronal activation at hypothalamic sites important
to the central control of energy homeostasis, such as the
arcuate and the paraventricular nuclei of the hypothal-
amus [28,29]. Hypothalamic neurons are densely inner-
vated by serotonergic terminals from dorsal raphe nucleus
(DRN) and 5-HT released at hypothalamic sites is recog-
nized as an important feeding inhibitory influence [5,9].
We presently show that an i.c.v. injection of IL-1β in
normal rats had a potent stimulatory effect on 5-HT
extracellular levels in the ventromedial hypothalamus, as
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Figure 2 Effect of ARG and IL-1β on hypothalamic 5-HIAA
levels. Levels of 5-hydroxy-indol-acetic acid, expressed as % of the
mean basal level, in 20-min VMH microdialysate samples. Upper
Panel: Samples collected before or up to 120 min after the i.c.v.
injection of 20 μg of L-arginine (ARG, n = 8) or vehicle (CSF, n = 9).
Values are means ± S.E.M. Lower Panel: Samples collected before or
up to 180 min after the i.c.v. injection of 10 ng of interleukin-1β, in
animals pretreated with 20 μg L-arginine (ARG + IL-1β, n = 8) or not
(IL-1β, n = 9). Values are means ±S.E.M.
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increments in the dialysate levels of 5-HIAA indicates that
stimulation of 5-HT synthesis probably did not contribute
to the stimulation of dialysate levels.
Available evidence on the effect of IL-1β upon central
serotonergic activity is controversial. Inhibitory effects
have been reported, as the cytokine has been found to
decrease the firing rate of DRN neurons in vitro [30]
and to activate the 5-HT transporter in both DRNNitric
Oxide
Interle
Foo
MSerotonin CRH
Figure 3 Schematic of potential central interactions involved in IL-1β
mediators and inhibition (dashed arrows) of orexigenic mediators. In
oxide stimulation (present results), does not affect IL-1β hypophagia, while
abolition of IL-1β hypophagia [15].neurons and striatum terminals [31]. However, stimula-
tory actions have also been described, such as increased
serotonergic transmission in the DRN [32] as well as
stimulation of hypothalamic 5-HT turnover and release
by IL-1β [33-35]. The present finding is in line with this
latter evidence and agrees with our previous observa-
tions in obese rats [15].
An important aspect addressed in the present work
was the influence of the acute treatment with the NOS
substrate ARG on hypothalamic 5-HT. Although a single
i.c.v. injection of ARG alone failed to modify the basal
levels of 5-HT and 5-HIAA in the microdialysates of the
ventromedial hypothalamus, the IL-1β-evoked stimula-
tion of hypothalamic 5-HT levels was prevented by the
pre-treatment with ARG. This agrees with other demon-
strations of serotonergic suppression after activation of
brain NO and of serotonergic stimulation by NOS inhib-
ition in various brain areas [36,37]. Likewise, a single
intraperitoneal injection of the inhibitor of NOS, NG-
nitro-L-arginine, increased 5-HT metabolism in the
diencephalon [19,20].
However, there are also reports showing divergent con-
sequences of acute manipulations of brain NO activity
upon the serotonergic system. For example, the adminis-
tration of ARG into the medial pre-optic area increased
local levels of 5-HT [38]. The NOS inhibitor N-nitro-L-ar-
ginine methylester failed to affect the increased hypothal-
amic 5-HT metabolism induced by IL-6 in mice [39] and
inhibition of NOS has been found to increase brain sero-
tonergic activity and metabolism while enhanced NO
activity has been accompanied by decreased 5-HT levels
[40,41]. A possible explanation for these discrepancies
could arise from the observation that 5-HT showed a bi-
phasic response to NO donors, with dosages in the low
range increasing 5-HT activity while high doses diminish-
ing it [42]. However, an opposite dual relation has also
been found, with low doses of NO donors decreasing and
high doses increasing 5-HT outflow [43]. Since the ARGukin-1β
d Intake
AgRPNPYelanocortins
hypophagia, showing stimulation (solid arrows) of anorexigenic
normal rats, loss of the serotonergic influence, as induced by nitric
the loss of serotonin is not compensated in obese rats, leading to
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levels per se, it is indicated that the participation of the
NO system on the mechanisms of the serotonergic stimu-
lation induced by IL-1β probably relies on complex inte-
ractions with other mediators.
Different lines of evidence suggested the participation
of hypothalamic 5-HT on the hypophagia evoked by IL-
1β. VMH serotonergic activity was increased in tumor
bearing or IL-1β peripherally-treated rats and the local
administration of a 5-HTantagonist attenuated hypophagia
in these animals [9,35]. Central IL-1β anorexia has also
been attenuated by the peripheral treatment with 5-HT2C
receptor antagonists, 5-HT1A auto receptor agonists or an
inhibitor of 5-HT synthesis [10,11]. IL-1β hypophagia has
been associated with activation of melanocortinergic neu-
rons in the paraventricular nuclei [29]. This is in agreement
with the previous findings concerning the importance of
5-HT to IL-1β anorexia, since the hypothalamic melano-
cortinergic system has been shown to mediate serotoner-
gic drug-induced hypophagia [44].
It is thus conceivable that, in the present experimental
settings, the serotonergic activation evidenced in the
VMH by the microdialysis technique, represented a mech-
anism favoring IL-1β-evoked feeding-inhibition. However,
the results also indicate that additional mechanisms were
involved, since hypophagia was still present when the 5-
HT increase was prevented. Other mediators of the hypo-
thalamic circuitry regulating energy homeostasis probably
contributed to the maintenance of IL-1β hypophagia dur-
ing serotonergic inhibition, as the cytokine reportedly
inhibited orexigenic neuropeptide Y neurons while it stim-
ulated anorexigenic melanocortinergic neurons [35]. This
suggestion is consistent with our earlier observation that,
in obese Zucker rats, the hypophagia induced by IL-1β
was totally dependent on the VMH serotonergic stimula-
tion [15]. We suggested that the absence of 5-HT could
not be overcome by the recruitment of other mechanisms
during IL-1β hypophagia, unlike the normal rats of the
present experiments.
Besides 5-HT, multiple central mechanisms have been
implicated in hypophagia induced by IL-1β, including
inhibition of glucose-sensitive neurons in the lateral hypo-
thalamic area and stimulation of glucose-responsive neu-
rons in the VMH [7,8]. Hypothalamic neuropeptide
systems have also been shown to be targeted by IL-1β.
Stimulation of anorexigenic peptides is one important ac-
tion of the cytokine leading to feeding inhibition. There
are demonstrations that corticotropin-releasing hor-
mone, arginine vasopressin, oxytocin, encephalin, chole-
cystokinin, and proopiomelanocortin, the precursor of
alpha melanocyte-stimulating hormone, all play a part
as IL-1β downstream effectors. Additionally, IL-1β re-
portedly inhibited the orexigenic mediators neuropep-
tide Y and agouti-related protein [7,8,18,45,46]. Thesedata indicate that a complex interplay of mediators un-
derlies IL-1β hypophagia and support the present sug-
gestion that one or more of these actions accounted for
the maintenance of the hypophagic effect of IL-1β, after
the serotonergic inhibition induced by ARG. Which ones
were more effective cannot be ascertained at present.
There are reports of impairment of multiple feeding-
control systems in obesity, not only in the Zucker
strain, but also in other rodent models and in humans
[5,23,47-51]. The Zucker mutation leads to severe lep-
tin resistance due the production of an inactive hy-
pothalamic leptin receptor. The blunted leptin action
induces upregulation of neuropeptide Y and agouti-related
protein and downregulation of proopiomelanocortin,
cocaine-amphetamine-related peptide, and corticotropin-
releasing hormone, among other defects [49-51]. In this
setting of multiple disruptions of feeding-regulatory sys-
tems, it is not surprising that the serotonergic inhibition
could not be compensated in obese Zucker rats, thus
abolishing IL-1β hypophagia [15]. Figure 3 shows an sche-
matic of potential central interactions involved in IL-1β
hypophagia.
In summary, the present data showed that one central
effect of IL-1β is serotonergic stimulation in the VMH,
an action inhibited by NO activity. It is suggested that,
although 5-HT participates in IL-1β anorexia, other
mechanisms recruited by IL-1β in normal rats are able
to override the absence of the serotonergic hypophagic
influence.Abbreviations
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